Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 7;74(8):1279-1292.
doi: 10.1136/gutjnl-2024-334010.

GPR171 restrains intestinal inflammation by suppressing FABP5-mediated Th17 cell differentiation and lipid metabolism

Fushun Kou #  1 , Xiao-Yu Li #  1 , Zhongsheng Feng #  1 , Jinghan Hua  1 , Xiaohan Wu  1 , Han Gao  1 , Jian Lin  1 , Dengfeng Kang  1 , Ai Li  1 , Junxiang Li  2 , Yao Ding  3 , Ting Ban  3 , Qing Zhang  3 , Zhanju Liu  4
Affiliations

GPR171 restrains intestinal inflammation by suppressing FABP5-mediated Th17 cell differentiation and lipid metabolism

Fushun Kou et al. Gut. .

Abstract

Background: GPR171 suppresses T cell immune responses involved in antitumour immunity, while its role in inflammatory bowel disease (IBD) pathogenesis remains unclear.

Objective: We aimed to investigate the role of GPR171 in modulating CD4+ T cell effector functions in IBD and evaluate its therapeutic potential.

Design: We analysed GPR171 expression in colon biopsies and peripheral blood samples from patients with IBD and assessed the impact of GPR171 on CD4+ T cell differentiation through administration of its endogenous ligand (BigLEN). We further determined the role of GPR171 in dextran sulfate sodium (DSS)-induced colitis and CD45RBhighCD4+ T-cell transfer colitis model and deciphered the underlying mechanisms using RNA sequencing (RNA-seq) and lipidomics. We developed a novel BigLEN-based Fc fusion protein (BigLEN-Fc) and evaluated its potential in preventing and treating colitis.

Results: GPR171 was markedly increased in inflamed mucosa and CD4+ T cells of patients with IBD compared with controls. BigLEN-triggered GPR171 activation inhibited Th17 cell differentiation in vitro. GPR171 deficiency exacerbated DSS- and CD45RBhighCD4+ T cell-induced colitis in mice, characterised by increased Th17 cell responses in intestinal mucosa. Mechanistically, GPR171 deficiency promoted Th17 cell differentiation and altered lipidome profile in Th17 cells via the cAMP-pCREB-FABP5 axis. Blockage of FABP5 reduced Th17 cell differentiation in vitro and ameliorated DSS-induced colitis in Gpr171 -/- mice. Furthermore, BigLEN-mutFc administration potently mitigated colitis in mice.

Conclusions: GPR171 deficiency promotes Th17 cell differentiation and causes lipid metabolism perturbation, contributing to intestinal inflammation in a FABP5-dependent manner. Target therapy (eg, BigLEN-Fc) represents a novel therapeutic approach for IBD treatment.

Keywords: INFLAMMATORY BOWEL DISEASE; INTESTINAL GENE REGULATION; INTESTINAL T CELLS; MUCOSAL IMMUNITY.

PubMed Disclaimer

Conflict of interest statement

Competing interests: In this research endeavor, YD, TB and QZ are employees of Ailomics Therapeutics . A patent application on using the BigLEN-fusion proteins to treat IBD has been filed by Ailomics Therapeutics. The BigLEN-fusion proteins used in this study was generously provided by Ailomomics Therapeutics for research purposes only. All authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

MeSH terms

LinkOut - more resources